Compare AKBA & UIS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AKBA | UIS |
|---|---|---|
| Founded | 2007 | 1942 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | EDP Services |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 251.0M | 220.2M |
| IPO Year | 2014 | 1994 |
| Metric | AKBA | UIS |
|---|---|---|
| Price | $1.22 | $3.16 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 4 |
| Target Price | $4.67 | ★ $5.67 |
| AVG Volume (30 Days) | ★ 4.1M | 927.3K |
| Earning Date | 05-07-2026 | 05-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 93.94 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $1,950,100,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $2.60 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.82 | $1.97 |
| 52 Week High | $3.81 | $4.98 |
| Indicator | AKBA | UIS |
|---|---|---|
| Relative Strength Index (RSI) | 46.66 | 34.69 |
| Support Level | $1.16 | $2.59 |
| Resistance Level | $1.52 | $3.29 |
| Average True Range (ATR) | 0.07 | 0.28 |
| MACD | -0.02 | -0.08 |
| Stochastic Oscillator | 7.59 | 1.65 |
Akebia Therapeutics Inc is a fully integrated biopharmaceutical company. The Company's operating segment is the business of developing and commercializing novel therapeutics. The current portfolio of the company includes Auryxia (ferric citrate), a medicine approved and marketed in the United States for the control of serum phosphorus levels in adult patients with dialysis-dependent chronic kidney disease and the treatment of iron deficiency anemia, in adult patients with non-dialysis-dependent chronic kidney disease, Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, inhibitor approved in Japan for the treatment of anemia due to chronic kidney disease, and HIF-PH inhibitors in preclinical development.
Unisys Corp is engaged in the provision of technology solutions for clients across the government, financial services, and commercial markets. It operates through three business segments: Digital Workplace Solutions (DWS),Cloud, Applications & Infrastructure Solutions (CA&I), and Enterprise Computing Solutions (ECS). DWS provides workplace solutions featuring intelligent workplace services, proactive experience management and collaboration tools to support business growth. CA&I which provides digital transformation in the areas of cloud migration and management. ECS which provides solutions that harness secure, high-intensity enterprise computing and enable digital services through software-defined operating environments. maximum of revenue is from CA&I segment.